Dr. Agarwal on Androgen Receptor Inhibitors for Prostate Cancer

Neeraj Agarwal, MD
Published: Wednesday, Dec 27, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Several AR inhibitors are being tested in the first-line setting, such as apalutamide, explains Agarwal. In the next 2 or 3 years, there will be multiple new AR inhibitors with their own benefits and adverse events.

According to Agarwal, it will be challenging for community oncologists to determine the ideal choice for patients with prostate cancer.
 
SELECTED
LANGUAGE


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses androgen receptor (AR) inhibitors for patients with prostate cancer.

Several AR inhibitors are being tested in the first-line setting, such as apalutamide, explains Agarwal. In the next 2 or 3 years, there will be multiple new AR inhibitors with their own benefits and adverse events.

According to Agarwal, it will be challenging for community oncologists to determine the ideal choice for patients with prostate cancer.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x